36.98
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt HROW?
Forum
Prognose
Aktiensplit
Harrow Inc Aktie (HROW) Neueste Nachrichten
What analysts say about Harrow Inc. stockFree Stock Market Trend Analysis - Autocar Professional
Harrow Inc. Stock Analysis and ForecastBreakneck growth rates - jammulinksnews.com
What drives Harrow Inc. stock priceHigh-octane financial growth - jammulinksnews.com
Is Harrow Inc. a good long term investmentRapid capital growth - jammulinksnews.com
Harrow, Inc. (HROW): A Bull Case Theory - Insider Monkey
Harrow jumps as Cantor initiates with Bullish view on conservative outlook - MSN
HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm - ETX View
Ladenburg Thalmann & Co. Keeps Their Buy Rating on Harrow Health (HROW) - The Globe and Mail
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW - FinancialContent
Harrow purchases US commercialization rights to Samsung Bioepis' biosimilar portfolio - Eyes On Eyecare
Samsung Bioepis Partners with Harrow to Expand US Ophthalmology Market - Asia Business Outlook
Harrow's Strategic Positioning in the $9B Ophthalmology Biosimilars Market: Unlocking Value Through Biosimilar Commercialization and Medicare Savings - AInvest
Samsung Bioepis signs U.S. partnership for ophthalmology biosimilar sales - Yonhap News Agency
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc.HROW - cnhinews.com
Harrow Enters Into Commercialization Agreement With Samsung Bioepis For Ophthalmology Biosimilars Portfolio In The United States - TradingView
Harrow Enters into Commercialization Agreement with Samsung Bioe - GuruFocus
Harrow acquires exclusive US rights to Samsung Bioepis eye drugs - Investing.com Australia
Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States - Business Wire
Harrow Secures Landmark Deal for First FDA-Approved Eye Disease Biosimilars from Samsung Bioepis - Stock Titan
Q2 Earnings Estimate for Harrow Issued By William Blair - Defense World
(HROW) Trading Report - news.stocktradersdaily.com
FY2026 Earnings Estimate for Harrow Issued By William Blair - Defense World
Why Harrow Inc. stock attracts strong analyst attentionBreakout Level Watch - Newser
How Harrow Inc. stock performs during market volatilityTop Performing Stocks - Newser
What makes Harrow Inc. stock price move sharplyFree Stock Portfolio Optimization - Newser
Harrow (HROW) Stock Jumps 11.4%: Will It Continue to Soar? - Yahoo Finance
HROW’s Stock Performance: A Year of Mixed Fortunes & Market Shifts - investchronicle.com
Harrow (NASDAQ:HROW) Coverage Initiated at Cantor Fitzgerald - Defense World
Harrow Shares Soar 11.35% on Cantor Fitzgerald's Overweight Rating - AInvest
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):